MLICM
DNTH icon

Metropolitan Life Insurance Company (MetLife)’s Dianthus Therapeutics DNTH Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-453
Closed -$110K – 2517
2019
Q4 		$110K Sell
453
-11
-2% -$2.06K ﹤0.01% 2279
2019
Q3 		$76.1K Buy
464
+363
+359% +$69K ﹤0.01% 2444
2019
Q2 		$23.9K Buy
+101
New +$25K ﹤0.01% 2581

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s DNTH Position: Q1 2020 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Dianthus Therapeutics (DNTH) in Q1 2020, closing a stake of 453 shares — an estimated $110K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in DNTH in Q2 2019 and held it in 3 quarters. The position peaked at $110K in Q4 2019. 72 funds tracked by Wall St. Rank hold DNTH as of Q1 2020.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Dianthus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 453 Dianthus Therapeutics shares in Q1 2020, an estimated $110K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Dianthus Therapeutics in Q2 2019 and held it in 3 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Dianthus Therapeutics position peaked at $110K in Q4 2019.
  • 72 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2020.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2020, filed 15 May 2020.